announced its financial outlook for next year, saying it expects double-digit earnings and sales gains over 2006.
The medical-device maker expects to bring in between $8.65 billion and $9.45 billion in sales, up 11% to 21% from this year, the company said at a meeting with analysts Monday.
Sales of its Taxus stents are expected to range from $2.26 billion to $2.7 billion for 2007. In the U.S., sales of the stent system should be between $1.45 billion and $1.75 billion, Boston Scientific says.
The stents, which prop open arteries cleared of plaque, are pitted directly against
Johnson & Johnson's
Cypher stent. Both are coated with a drug meant to prevent reclogging.
Worldwide sales in Boston Scientific's cardiac-rhythm management group, which includes pacemakers and implantable cardioverter defibrillators, are forecast at $1.96 billion to $2.23 billion next year. Of that, approximately $1.3 billion to $1.49 billion in sales are expected to be in the U.S.
The news boosted Boston Scientific's stock nearly 3% to $16.87.